Compare · BIO vs CTKB
BIO vs CTKB
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Cytek Biosciences Inc. (CTKB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and CTKB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $10.39B, about 17.5x CTKB ($594.0M).
- Over the past year, BIO is up 32.3% and CTKB is up 11.8% - BIO leads by 20.5 points.
- CTKB has been more active in the news (14 items in the past 4 weeks vs 2 for BIO).
- CTKB has more recent analyst coverage (13 ratings vs 12 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- Cytek Biosciences Inc.
- Price
- -
- -
- Market cap
- $10.39B
- $594.0M
- 1M return
- +17.31%
- +2.69%
- 1Y return
- +32.33%
- +11.84%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2021
- News (4w)
- 2
- 14
- Recent ratings
- 12
- 13
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Latest CTKB
- Cytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- PRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax
- Director Muir Glenn P converted options into 3,086 shares (SEC Form 4)
- Director Holder Michael converted options into 2,181 shares, increasing direct ownership by 4% to 62,875 units (SEC Form 4)
- Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 27% to 28,499 units (SEC Form 4)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 33,270 shares and covered exercise/tax liability with 8,088 shares, increasing direct ownership by 0.52% to 4,821,870 units (SEC Form 4) (tax withholding)
- SEC Form 4 filed by Chief Legal Officer, Secretary Feuchtwang Ilan
- Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.